CooperCompanies, leading company in medical devices, announced that Walter M Rosebrough Jr has been appointed as an independent member of its Board of Directors effective January 3, 2026. Alongside this appointment, the company has entered a cooperation agreement with Browning West LP. Mr. Rosebrough will serve on the Board’s Corporate Governance and Nominating Committee, and the Board has indicated that by the end of 2026, it will seriously consider him for the position of Chair. The company also plans to identify and appoint an additional independent director with medical technology experience, with the agreement of Browning West.
Health Technology Insights: EDX Medical to Launch Advanced Bowel Cancer Test in UK
Mr. Rosebrough currently holds the position of CEO Emeritus and Senior Advisor at STERIS plc, a global medical device company specializing in infection prevention products and services. During his tenure as CEO of STERIS from 2007 to 2021, the company delivered a total return of ten times its stock value, equivalent to an annualized return of 18 percent, compared to the S&P 500’s 10 percent, and grew its market capitalization by more than $20 billion. Prior to that, he spent nearly 20 years at Hill-Rom Holdings, serving in senior roles including President and CEO of Support Systems International and President and CEO of Hill-Rom. Currently, he also serves as the Independent Chair of the Board at Varex Imaging, Nasdaq ticker VREX.
Health Technology Insights: Celltrion Wins CHMP Support for SteQeyma Autoinjector
Colleen Jay, the incoming Chair of CooperCompanies’ Board, said, “We are excited to welcome Walt to our Board. His decades of leadership in the medical device and healthcare industries, along with his proven record of creating long-term growth, will be invaluable in supporting our strategic priorities and delivering sustained value for our shareholders.”
Usman S. Nabi, Co-Founder and Chief Investment Officer of Browning West, stated, “Cooper has significant long-term potential. We are pleased to have reached a constructive agreement with the Board, and Walt’s appointment combined with plans for Board renewal position Cooper to achieve the critical initiatives required to unlock long-term shareholder value.”
Browning West has committed to standard standstill and voting arrangements under the Cooperation Agreement and will support the full Board slate at the 2026 Annual Meeting of Stockholders. The company will file the Cooperation Agreement as an exhibit to its Current Report on Form 8-K with the U.S. Securities and Exchange Commission.
Health Technology Insights: Cosan Secures Growth Funding to Expand AI Virtual Care
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- GlobeNewswire
